Hiperparatiroidismo secundario en enfermedad renal crónica

Con los cambios en los estilos de vida ha aumentado la incidencia de enfermedades cardiometabólicas causantes del incremento de enfermedad renal crónica, asociándose, en estadios avanzados, a complicaciones secundarias como es el hiperparatiroidismo, las cuales aumentan de manera importante la morbi...

Full description

Autores:
Araque Esquivel, Luz Marina
Flórez Moncada, Alejandro de Jesús
Rivera Larios, David Ernesto
Tipo de recurso:
Trabajo de grado de pregrado
Fecha de publicación:
2016
Institución:
Universidad Libre
Repositorio:
RIU - Repositorio Institucional UniLibre
Idioma:
spa
OAI Identifier:
oai:repository.unilibre.edu.co:10901/10234
Acceso en línea:
https://hdl.handle.net/10901/10234
Palabra clave:
Hiperparatiroidismo
Enfermedad renal cronica
Medicina
Secondary hyperparathyroidism
Parathyroid hormone
Vitamin D
Chronic renal failure
Renal osteodystrophy
HIPERPARATIROIDISMO
HORMONAS PARATIROIDEAS
ENFERMEDADES RENALES
Hiperparatiroidismo secundario
Hormona paratiroidea
Vitamina D
Insuficiencia renal crónica
Osteodistrofia renal
Rights
restrictedAccess
License
http://creativecommons.org/licenses/by-nc-nd/2.5/co/
id RULIBRE2_c6d8ea04240ca5679c2f192a8d353457
oai_identifier_str oai:repository.unilibre.edu.co:10901/10234
network_acronym_str RULIBRE2
network_name_str RIU - Repositorio Institucional UniLibre
repository_id_str
dc.title.spa.fl_str_mv Hiperparatiroidismo secundario en enfermedad renal crónica
title Hiperparatiroidismo secundario en enfermedad renal crónica
spellingShingle Hiperparatiroidismo secundario en enfermedad renal crónica
Hiperparatiroidismo
Enfermedad renal cronica
Medicina
Secondary hyperparathyroidism
Parathyroid hormone
Vitamin D
Chronic renal failure
Renal osteodystrophy
HIPERPARATIROIDISMO
HORMONAS PARATIROIDEAS
ENFERMEDADES RENALES
Hiperparatiroidismo secundario
Hormona paratiroidea
Vitamina D
Insuficiencia renal crónica
Osteodistrofia renal
title_short Hiperparatiroidismo secundario en enfermedad renal crónica
title_full Hiperparatiroidismo secundario en enfermedad renal crónica
title_fullStr Hiperparatiroidismo secundario en enfermedad renal crónica
title_full_unstemmed Hiperparatiroidismo secundario en enfermedad renal crónica
title_sort Hiperparatiroidismo secundario en enfermedad renal crónica
dc.creator.fl_str_mv Araque Esquivel, Luz Marina
Flórez Moncada, Alejandro de Jesús
Rivera Larios, David Ernesto
dc.contributor.advisor.none.fl_str_mv Iglesias Acosta, Jesús
Pertuz Pinzón, Adolfo
dc.contributor.author.none.fl_str_mv Araque Esquivel, Luz Marina
Flórez Moncada, Alejandro de Jesús
Rivera Larios, David Ernesto
dc.subject.spa.fl_str_mv Hiperparatiroidismo
Enfermedad renal cronica
Medicina
topic Hiperparatiroidismo
Enfermedad renal cronica
Medicina
Secondary hyperparathyroidism
Parathyroid hormone
Vitamin D
Chronic renal failure
Renal osteodystrophy
HIPERPARATIROIDISMO
HORMONAS PARATIROIDEAS
ENFERMEDADES RENALES
Hiperparatiroidismo secundario
Hormona paratiroidea
Vitamina D
Insuficiencia renal crónica
Osteodistrofia renal
dc.subject.subjectenglish.eng.fl_str_mv Secondary hyperparathyroidism
Parathyroid hormone
Vitamin D
Chronic renal failure
Renal osteodystrophy
dc.subject.lemb.spa.fl_str_mv HIPERPARATIROIDISMO
HORMONAS PARATIROIDEAS
ENFERMEDADES RENALES
dc.subject.proposal.spa.fl_str_mv Hiperparatiroidismo secundario
Hormona paratiroidea
Vitamina D
Insuficiencia renal crónica
Osteodistrofia renal
description Con los cambios en los estilos de vida ha aumentado la incidencia de enfermedades cardiometabólicas causantes del incremento de enfermedad renal crónica, asociándose, en estadios avanzados, a complicaciones secundarias como es el hiperparatiroidismo, las cuales aumentan de manera importante la morbimortalidad, estancia hospitalaria y menor calidad de vida. El conocimiento de la fisiopatología de estas alteraciones se ha profundizado en los últimos años, pasando de un modelo clásico de metabolismo fosfocálcico y hueso, a hablar de factores de crecimiento y conceptos importantes de biología molecular, permitiendo investigar nuevas dianas terapéuticas, modificando la forma de enfocar este tipo de pacientes. Por todo esto el hiperparatiroidismo secundario y las alteraciones del metabolismo mineral-óseo son campo importante en la investigación. Se realiza una revisión de la literatura clásica y actual con el objetivo de fundamentar los tópicos más relevantes sobre el tema.
publishDate 2016
dc.date.created.none.fl_str_mv 2016
dc.date.accessioned.none.fl_str_mv 2017-07-26T16:26:26Z
dc.date.available.none.fl_str_mv 2017-07-26T16:26:26Z
dc.type.local.spa.fl_str_mv Tesis de Especialización
dc.type.hasversion.spa.fl_str_mv info:eu-repo/semantics/acceptedVersion
dc.type.coar.spa.fl_str_mv http://purl.org/coar/resource_type/c_7a1f
dc.type.driver.spa.fl_str_mv info:eu-repo/semantics/bachelorThesis
format http://purl.org/coar/resource_type/c_7a1f
status_str acceptedVersion
dc.identifier.uri.none.fl_str_mv https://hdl.handle.net/10901/10234
dc.identifier.instname.spa.fl_str_mv instname:Universidad Libre
dc.identifier.reponame.spa.fl_str_mv reponame:Repositorio Institucional Universidad Libre
url https://hdl.handle.net/10901/10234
identifier_str_mv instname:Universidad Libre
reponame:Repositorio Institucional Universidad Libre
dc.language.iso.none.fl_str_mv spa
language spa
dc.relation.references.SPA.fl_str_mv Cuenta de alto costo.org [Internet]. Colombia: Cuenta de alto costo; 2008 [Actualizado el 30 junio 2015; citado 1 marzo 2016]. Disponible en: https://cuentadealtocosto.org/site/index.php/publicaciones
Ministerio de Salud y Protección Social. [Internet]. Colombia: Ministerio de salud y protección social. Dirección de Epidemiología y Demografía. Grupo de Gestión de Conocimiento. 2014 [Actualizado el 1 de enero de 2014; citado 1 marzo de 2016] Disponible en https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/ED/G CFI/OERCAV_001%2022.10.2013%20v1.pdf
Benjumea A., Manjarrés G, Arnoby J. Seguimiento de un programa de prediálisis en una unidad renal de la ciudad de Manizales. Rev. Colomb. Nefrol. 2015; 2(2):111–118.
Escobar M; Registro Español de Enfermos Renales (REER). Registro Español de Enfermos Renales. Informe 2013 y evolución 2007-2013. Nefrología 2016;36(2):97–120
López-Gómez JM, Abad S, Vega A. Nuevas expectativas en el tratamiento de la anemia en la enfermedad renal crónica. Nefrología. 2016; 36(3):232- 236.
Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM.. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension. 2001;38(4):938-42.
Perales Montilla CM, Duschek S, Reyes Del Paso GA. Calidad de vida relacionada con la salud en la enfermedad renal crónica: relevancia predictiva del estado de ánimo y la sintomatología somática. Nefrología. 2016 ;36(3):275-282
Cheng S. Trastornos minerales y óseos. En: Daugirdas J. Manual de tratamiento de la enfermedad renal crónica. 1ra Edición. España: Wolters Kluwer; 2012. Página 107-126.
Arango J, García A, Gómez R, Leguizamón H, Rodríguez K, Delgado V, et al. Recomendaciones para el manejo de las alteraciones del metabolismo óseo y mineral en el paciente con enfermedad renal crónica (EOMERC).Revista Colombiana de Nefrologia.2009
Torregrosa JV, Bover J, Cannata Andía J, Lorenzo V, de Francisco AL, Martínez I, et al. Recomendaciones de la Sociedad Española de Nefrología para el manejo de las alteraciones del metabolismo óseo-mineral en los pacientes con enfermedad renal crónica (S.E.N.-M.M.). Nefrologia. 2011;31(Suppl.1):3-32
Prieto S. Control del metabolismo del calcio, fósforo y magnesio. En: Tresguerres F, Ariznavarreta C, Cachofeiro V, Cardinali D, Loyzaga P, Lahera Juliá V, et al, editores. Fisiología Humana. 3ra Edición. México: McGraw-Hill; 2005. Pag 964-980
Hall JE, Guyton AC. Tratado de fisiología medica. 12va Edición. España: Elsevier; 2011.
Koeppen B, Stanton B. Berne y Levy: Fisiología. 6ta Edición. España: Elsevier; 2009.
Potts JT; Jüppner H. Trastornos de las glándulas paratiroides y homeostasis del calcio. En: Longo D, Kasper D, Jameson J, et al, editores. Harrison: Principios de Medicina Interna. Volumen 18 Edición. México: Mc Graw Hill; 2012. Pág 3096- 3119.
Fisiopatología del hueso y de la osteoporosis Dra. Amanda Páez Talero Médica Endocrinóloga, Universidad Nacional de Colombia Hospital Central de la Policía, Bogotá. Pag 12
Salech F, Couve A, Michea L, Alvo M. Klotho: un nuevo eslabón en la fisiopatología de la insuficiencia renal crónica. Rev Hosp Clín Univ Chile. 2010;21:142-146
Bover J. Egido J. Vitamina D, receptor de la vitamina D e importancia de su activación en el paciente con enfermedad renal crónica. Nefrologia 2015;35(1):28-41
Bellorin-Font E, Ambrosoni P, Carlini R, et al. Guías de práctica clínica para la prevención, diagnóstico, evaluación y tratamiento de los trastornos minerales y óseos en la enfermedad renal crónica (TMO-ERC) en adultos. Nefrología 2013;33(Suppl.1):1-28
Trujillo-Cuellar Hernando, Sierra-Lara Martínez J Daniel y Osorno-Solís Lucía. Alteraciones del metabolismo mineral y óseo asociadas a la enfermedad renal crónica. Revista Médica MD. 2015 5(3):151-160pp
Sellares VL, Torregrosa V. Alteraciones del metabolismo mineral en la enfermedad renal crónica estadios III, IV y V (no en diálisis). Nefrología (2008) Supl. 3, 67-78.
dc.relation.references.eng.fl_str_mv United States Renal Data System, 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States. National Institutes of Health. National Institute of Diabetes Mellitus and Digestive and Kidney Diseases. Bethesda. 2014
White SL, Chadban SJ, Jan S, Chapman JR, Cass A. How can we achieve global equity in provision of renal replacement therapy?. Bull World Health Organ. 2008; 86(3):229-237.
Kovesdy CP1 , Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K. Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int. 2008;73(11):1296- 1302
Collins AJ, Foley RN, Gilbertson DT, Chen SC. United States Renal Data System public health surveillance of chronic kidney disease and end-stage renal disease. Kidney Int Suppl (2011). 2015;5(1):2-7.
Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010; 375(9731):2073-2081
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney int, Suppl. 2013; 3:1–150
Uhlig K, Berns JS, Kestenbaum B, Kumar R, Leonard MB, Martin KJ, et al. KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis. 2010 May;55(5):773-99
Nasrallah MM, El-Shehaby AR, Osman NA, Fayad T, Nassef A, Salem MM, et al. The association between fibroblast growth factor-23 and vascular 101 calcification is mitigated by inflammation markers. Nephron Extra. 2013;3(1):106-112.
Dai B, David V, Martin A, Huang J, Li H, Jiao Y, et al. A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model. PLoS One. 2012;7(9):1–15, e44161
Bover J, Egido J, Fernández-Giráldez E, Praga M, Solozábal-Campos C, Torregrosa JV, et al. Vitamina D, receptor de la vitamina D e importancia de su activación en el paciente con enfermedad renal crónica. Nefrologia 2015;35(1):28-41
Silver J, Levi R. Regulation of PTH synthesis and secretion relevant to the management of secondary hyperparathyroidism in chronic kidney disease, Kidney Int Suppl. 2005;(95):Pag 8-12.
Smith DH, Johnson ES, Thorp ML, Yang X, Neil N. Hyperparathyroidism in chronic kidney disease: a retrospective cohort study of costs and outcomes. J Bone Miner Metab. 2009;27(3):287-94
Smith DH, Johnson ES, Thorp ML, Yang X, Neil N. Hyperparathyroidism in chronic kidney disease: a retrospective cohort study of costs and outcomes. J Bone Miner Metab. 2009;27(3):287-94
Hogan J, Goldfarb S, Sterns R, Lam AQ. Regulation of calcium and phosphate balance. [Internet]. Up to Date. [11 dic 2014; citado 1 junio 2016]. Disponible en: http://www.uptodate.com.ezproxy.unilibrebaq.edu.co:8084/contents/regulati on-of-calcium-and-phosphatebalance?source=search_result&search=Regulation+of+calcium+and+phosp hate+balance&selectedTitle=1~150
Hoenderop JG, Nilius B, Bindels RJ. Calcium absorption across epithelia. Physiol Rev. 2005;85(1):373-422
Hoenderop JG, Nilius B, Bindels RJ. Calcium absorption across epithelia. Physiol Rev. 2005;85(1):373-422
Hofer AM, Brown EM. Extracellular calcium sensing and signalling. Nat Rev Mol Cell Biol. 2003;4(7):530-538.
Peng JB, Brown EM, Hediger MA. Apical entry channels in calciumtransporting epithelia. News Physiol Sci. 2003;18:158-63.
Quarles LD. Endocrine functions of bone in mineral metabolism regulation. J Clin Invest. 2008;118(12):3820-3828.
Quarles LD. Endocrine functions of bone in mineral metabolism regulation. J Clin Invest. 2008;118(12):3820-3828.
Berndt T, Kumar R. Novel mechanisms in the regulation of phosphorus homeostasis. Physiology (Bethesda). 2009;24:17-25.
.Silver J, Naveh-Many T. Phosphate and the parathyroid. Kidney Int. 2009;75(9):898-905.
.Silver J, Naveh-Many T. Phosphate and the parathyroid. Kidney Int. 2009;75(9):898-905.
Fuleihan GE, Brown E. Parathyroid hormone secretion and action. [Internet]. Up to date; [14 marzo 2014; 1 junio 2016]. Disponible en: http://www.uptodate.com.ezproxy.unilibrebaq.edu.co:8084/contents/parathyr oid-hormone-secretion-and- action?source=search_result&search=Parathyroid+hormone+secretion+and +action&selectedTitle=1~150.
Chen Ra, Goodman WG. Role of the calcium-sensing receptor in parathyroid gland physiology. Am J Physiol Renal Physiol. 2004; 286(6):1005-1011.
Karsenty G, Ferron M. The contribution of bone to whole-organism physiology. Nature. 2012;481(7381):314-320
Toro L. Rol de Klotho y FGF23 en la regulación del fosfato y calcio plasmático, Rev Hosp Clin Univ Chile 2010;21:Pag 25–32
Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997;390:45-51.
Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, et al. Targeted ablation of FGF23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest. 2004;113(4):561–8.
Ming CH, Shiizaki K, Kuro-o M, Moe OS. Fibroblast Growth Factor 23 and Klotho: Physiology and Pathophysiology of an Endocrine Network of Mineral Metabolism. Annu Rev Physiol. 2013; 75: 503–533.
Chen CY, Kuro M, Razzaque MS. Molecular regulation of phosphate metabolism by fibroblast growth factor -23-khloto system. Advances in Chronic Kidney Disease. 2011; Vol 18, No 2: pp 91-97
Haussler MR, Whitfield GK, Kaneko I, Forster R, Saini R, Hsieh JC, et al. The role of vitamin D in the FGF23, Klotho, and phosphate bone-kidney endocrine axis. Rev Endocr Metab Disord. 2012;13(1):57–69
Yajima A, Tsuchiya K, Yokota H, Niita K. Bone disease in the field of CKDMBD. Clin Calcium. 2016;26(6):875-880
Telci D, Dogan AU, Ozbek E, Polat EC, Simsek A, Cakir SS, et al. KLOTHO Gene Polymorphism of G395A Is Associated with Kidney Stones. Am J Nephrol. 2011; 33:337–343
Akimoto T, Yoshizawa H, Watanabe Y, Numata A, Yamazaki T, Takeshima E, et al. Characteristics of urinary and serum soluble Klotho protein in patients with different degrees of chronic kidney disease. BMC Nephrology. 2012;13:155
Shimamura Y, Hamada K, Inoue K, Ogata K, Ishihara M, et al. Serum levels of soluble secreted a-Klotho are decreased in the early stages of chronic kidney disease, making it a probable novel biomarker for early diagnosis, Clin Exp Nephrol.2012;16:722–729
Young GH, Wu VC. KLOTHO methylation is linked to uremic toxins and chronic kidney disease, Kidney Int. 2012;81(7):611-612
Specker BL, Tsang RC, Hollis BW. Effect of race and diet on human-milk vitamin D and 25-hydroxyvitamin D. Am J Dis Child.1985;139(11):1134- 1137.
Wallace TC, Reider C, Fulgoni VL 3rd. Calcium and vitamin D disparities are related to gender, age, race, household income level, and weight classification but not vegetarian status in the United States: analysis of the NHANES 2001-2008 data set. J Am Coll Nutr. 2013; 32:321–330.
Lamberg-Allardt C, Karkkainen M, Seppanen R, Bistrom H. Low serum 25- hydroxyvitamin D concentrations and secondary hyperparathyroidism in middle-aged white strict vegetarians. Am J Clin Nutr. 1993;58:684–689
Barrett E, Barrett P. The parathyroid glands and vitamin D. En: Boron WF, Boulpaep EL, editors. Medical Physiology. 2nd Edition. United States of America: Elsevier; 2012.Pag 1094-1110
Du X, Greenfield H, Fraser DR, Ge K, Trube A, Wang Y. Vitamin D deficiency and associated factors in adolescent girls in Beijing. Am J Clin Nutr. 2001;74(4):494–500
Munns C, Zacharin MR, Rodda CP, et al. Prevention and treatment of infant and childhood vitamin D deficiency in Australia and New Zealand: A consensus statement. Med J Aust. 2006;185:268–272
Van Cromphaut SJ, Dewerchin M, Hoenderop JG, et al. Duodenal calcium absorption in vitamin D receptor-knockout mice: Functional and molecular aspects. Proc Natl Acad Sci U S A. 2001;98(23):13324-13329
Wasserman RH. Vitamin D and the intestinal absorption of calcium: A view and overview. In: Feldman D, Pike JW, Glorieux FH, eds. Vitamin D. San Diego (CA): Academic Press. 2005:411–428.
Yamamoto Y, Yoshizawa T, Fukuda T, et al. Vitamin D receptor in osteoblasts is a negative regulator of bone mass control. Endocrinology. 2013;154(3):1008-1020.
Slatopolsky E. The intact nephron hypothesis: the concept and its implications for phosphate management in CKD-related mineral and bone disorder. Kidney Int Suppl. 2011;(121):S3-8.
Kovesdy CP, Kalantar-Zadeh K: Bone and mineral disorders in pre-dialysis CKD. Int Urol Nephrol.2008;40:427-440.
Astudillo J, Cocio R, Ríos D. Osteodistrofia renal y trastornos del metabolismo y la mineralización ósea asociados a enfermedad renal crónica: Manifestaciones en radiología. Rev. chil. radiol. [Internet]. 2016 [citado 2016 Jun 10] ; 22( 1 ): 27-34. Disponible en: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717- 93082016000100008&lng=es. http://dx.doi.org/10.1016/j.rchira.2016.02.002
Kumar R, Thompson JR. The regulation of parathyroid hormone secretion and synthesis. J Am Soc Nephrol. 2011;22(2):216-224.
Melamed ML, Eustace JA, Plantiga LC, Jaar BG, et al. Third generation parathyroid hormone assay and all-cause mortality in incident patients: The CHOICE study. Nephrol Dial Transplant. 2008;23(5):1650-1658.
Cole D, Webb S, Chan P. Update on parathyroid hormone: New tests and new challenges for external quality assessment. Clinical Biochemistry 2007; 40: 585–590
Lillo J, Olea M. Hormona paratiroidea. Formas moleculares y utilidad diagnóstica. Ed cont lab clín; 13: 33-48
Levin A, Hemmelgarn B, Culleton B, Tobe S, McFarlane P, Ruzicka M, et al. Canadian Society of Nephrology. Guidelines for the management of chronic kidney disease. CMAJ. 2008 Nov 18;179(11):1154-62.
Kidney Disease Outcomes Quality Initiative KDOQI. Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Disponible en http://www.kidney.org/professionals/kdoqi/guidelines_bone/index.htm
Martínez I, Saracho R, Ocharan J, Muñoz RJ, Montenegro J. Role of diet in the management of osteodystrophy during progressive renal insufficiency. Nefrologia 2003;23(Suppl 2):57-63.
Giovannucci E. Can vitamin D reduce total mortality? Arch Intern Med 2007;167(16):1709-10
Martínez I, Saracho R, Montenegro J, Llach F. The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis 1997;29(4):496-502
Torregrosa JV, Ramos AM. Use of bisphosphonates in chronic kidney disease. Nefrologia 2010;30(3):288-96.
Miller PD. Is there a role for bisphosphonates in chronic kidney disease? Semin Dial. 2007 May-Jun;20(3):186-90.
Palmer SC, McGregor DO, Macaskill P, Craig JC, Elder GJ, Strippoli GF. Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med. 2007 Dec 18;147(12):840-53.
Teng M, Wolf M, Lowrie E, Ofsthun N Lazaro JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003;349:446-56
Taal MW. Slowing the progression of adult chronic kidney disease: therapeutic advances. Drugs. 2004;64(20):2273-89.
Crawford PW, Lerma EV. Treatment options for end stage renal disease. Prim Care. 2008 Sep;35(3):407-32, v. Review.
Murtagh FE, Addington-Hall JM, Donohoe P, Higginson IJ. Symptom management in patients with established renal failure managed without dialysis. EDTNA ERCA J. 2006 Apr-Jun;32(2):93-8.
Sociedad Española de Diálisis y Trasplante (SEDYT). [sede Web]. Sánchez-Casajús A, Gabás J, Álvarez-Lipe R, Barceló P, Genovés A, Izaguirre A, et al. [Acceso Junio 8 de 2016]. Inicio de Diálisis: Consensos SEDYT ¿Cómo Y Cuándo Iniciar Diálisis? Disponible en: http://www.sedyt.org/2004/consensos/inicio_dialisis.htm
Zehnder C, Gutzwiller JP, Renggli K. Hemodiafiltration-a new treatment option for hyperphosphatemia in hemodialysis patients. Clin Nephrol 1999;52:152-9.
Locatelli F, Buoncristiani U, Canaud B, Kohler H, Petitclerc T, Zucchelli P. Dialysis dose and frequency. Nephrol Dial Transplant 2005;20:285-96.
Sprague SM, Abboud H, Qiu P, Dauphin M, Zhang P, Finn W. Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clin J Am Soc Nephrol. 2009 Jan;4(1):178-85
Goldsmith DR, Scott LJ, Cvetkovic RS, Plosker GL. Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis. Drugs. 2008;68(1):85-104.
Goldsmith DR, Scott LJ, Cvetkovic RS, Plosker GL. Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis. Drugs. 2008;68(1):85-104.
Suki WN, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L et al. Effects of sevelamer and calcium-basel phosphate binders on mortality in hemodialysis patients. Kidney Int 2007;72:1130-7.
Suki WN, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L et al. Effects of sevelamer and calcium-basel phosphate binders on mortality in hemodialysis patients. Kidney Int 2007;72:1130-7.
Tentori F, Hunt WC, Stidley CA, Rohrscheib MR, Bedrick EJ, Meyer KB, Johnson HK, Zager PG; Medical Directors of Dialysis Clinic Inc. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int. 2006 Nov;70(10):1858-65.
Cunningham J. New Vitamin D analogues for osteodystrophy in chronic kidney disease. Pediatr Nephrol. 2004 Jul;19(7):705-8.
Cardus A, Panizo S, Parisi E, Fernández E, Valdivieso JM. Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res 2007;22:860-6. 62. Charra B, Chazot C, Jean G et al. Long 3 x 8 hr dialysis: a threedecade summary. J Nephrol 2003;(S7):S64-S69.
Cardus A, Panizo S, Parisi E, Fernández E, Valdivieso JM. Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res 2007;22:860-6. 62. Charra B, Chazot C, Jean G et al. Long 3 x 8 hr dialysis: a threedecade summary. J Nephrol 2003;(S7):S64-S69.
Arenas MD, Alvarez-Ude F, Gil MT, Moledous A, Malek T, Nuñez C et al. Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis. Nephrol Dial Transplant. 2007 Jun;22(6):1639-44.
Garside R, Pitt M, Anderson R, Mealing S, Roome C, Snaith A et al. The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation. Health Technol Assess. 2007 May;11(18):iii, xi-xiii, 1-167.
Palmer SC, Strippoli GF, McGregor DO. Interventions for preventing bone disease in kidney transplant recipients: a systematic review of randomized controlled trials. Am J Kidney Dis. 2005 Apr;45(4):638-49.
Egbuna OI, Taylor JG, Bushinsky DA. Elevated calcium phosphate product after renal transplantation is a risk factor for graft failure. Clin Transplant 2007;21:558.
Peters BS, Moyses RM, Jorgetti V, Martini LA. Effects of parathyroidectomy on bone remodeling markers and vitamin D status in patients with chronic kidney disease-mineral and bone disorder. Int Urol Nephrol. 2007;39(4):1251-6.
Cejka D, Benesch T, Krestan C, Roschger P, Klaushofer K, Pietschmann P, et al. Effect of teriparatide on early bone loss after kidney transplantation. Am J Transplant 2008;8(9):1864-70.
Wilmer WA, Magro CM. Calciphylaxis: emerging concepts in prevention, diagnosis, and treatment. Semin Dial 2004;15(3):172-86.
Hayden MR, Goldsmith DJ. Sodium thiosulfate: new hope for the treatment of calciphylaxis. Semin Dial 2010;23(3):258-62.
dc.rights.uri.*.fl_str_mv http://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.rights.license.*.fl_str_mv Atribución-NoComercial-SinDerivadas 2.5 Colombia
dc.rights.accessrights.spa.fl_str_mv info:eu-repo/semantics/restrictedAccess
dc.rights.coar.spa.fl_str_mv http://purl.org/coar/access_right/c_16ec
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-nd/2.5/co/
Atribución-NoComercial-SinDerivadas 2.5 Colombia
http://purl.org/coar/access_right/c_16ec
eu_rights_str_mv restrictedAccess
dc.format.none.fl_str_mv PDF
dc.format.mimetype.none.fl_str_mv application/pdf
dc.coverage.spatial.spa.fl_str_mv Barranquilla
institution Universidad Libre
bitstream.url.fl_str_mv http://repository.unilibre.edu.co/bitstream/10901/10234/1/MONOGRAFIA%20HIPERPARATIROIDISMO%20SECUNDARIO%20EN%20ENFERMEDAD%20RENAL%20CR%c3%93NICA.pdf
http://repository.unilibre.edu.co/bitstream/10901/10234/2/license.txt
http://repository.unilibre.edu.co/bitstream/10901/10234/3/MONOGRAFIA%20HIPERPARATIROIDISMO%20SECUNDARIO%20EN%20ENFERMEDAD%20RENAL%20CR%c3%93NICA.pdf.jpg
bitstream.checksum.fl_str_mv 5ad84697961a7768bf5e32629d786423
8a4605be74aa9ea9d79846c1fba20a33
01ab6ba395b7a3206f5556e6552a5672
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Institucional Unilibre
repository.mail.fl_str_mv repositorio@unilibrebog.edu.co
_version_ 1814090399641239552
spelling Iglesias Acosta, JesúsPertuz Pinzón, AdolfoAraque Esquivel, Luz MarinaFlórez Moncada, Alejandro de JesúsRivera Larios, David ErnestoBarranquilla2017-07-26T16:26:26Z2017-07-26T16:26:26Z2016https://hdl.handle.net/10901/10234instname:Universidad Librereponame:Repositorio Institucional Universidad LibreCon los cambios en los estilos de vida ha aumentado la incidencia de enfermedades cardiometabólicas causantes del incremento de enfermedad renal crónica, asociándose, en estadios avanzados, a complicaciones secundarias como es el hiperparatiroidismo, las cuales aumentan de manera importante la morbimortalidad, estancia hospitalaria y menor calidad de vida. El conocimiento de la fisiopatología de estas alteraciones se ha profundizado en los últimos años, pasando de un modelo clásico de metabolismo fosfocálcico y hueso, a hablar de factores de crecimiento y conceptos importantes de biología molecular, permitiendo investigar nuevas dianas terapéuticas, modificando la forma de enfocar este tipo de pacientes. Por todo esto el hiperparatiroidismo secundario y las alteraciones del metabolismo mineral-óseo son campo importante en la investigación. Se realiza una revisión de la literatura clásica y actual con el objetivo de fundamentar los tópicos más relevantes sobre el tema.With changing lifestyles it has increased the incidence of cardiometabolic diseases causing increased chronic kidney disease, associated, in advanced stages, to secondary complications such as hyperparathyroidism, which increase significantly the mortality and morbidity, hospital stay and lower quality of life. Knowledge of the pathophysiology of these disorders has deepened in recent years from a classic model of calcium and phosphorus metabolism and bone, to speak of growth factors and concepts of molecular biology, allowing research new therapeutic targets, changing the way focus these patients. For all this secondary hyperparathyroidism and disturbances of bone-mineral metabolism are important in the research field. This is a review of classical and current literature is done with the objective to support the most relevant topics on the subject.PDFapplication/pdfspahttp://creativecommons.org/licenses/by-nc-nd/2.5/co/Atribución-NoComercial-SinDerivadas 2.5 Colombiainfo:eu-repo/semantics/restrictedAccesshttp://purl.org/coar/access_right/c_16ecHiperparatiroidismoEnfermedad renal cronicaMedicinaSecondary hyperparathyroidismParathyroid hormoneVitamin DChronic renal failureRenal osteodystrophyHIPERPARATIROIDISMOHORMONAS PARATIROIDEASENFERMEDADES RENALESHiperparatiroidismo secundarioHormona paratiroideaVitamina DInsuficiencia renal crónicaOsteodistrofia renalHiperparatiroidismo secundario en enfermedad renal crónicaTesis de Especializacióninfo:eu-repo/semantics/acceptedVersionhttp://purl.org/coar/resource_type/c_7a1finfo:eu-repo/semantics/bachelorThesisCuenta de alto costo.org [Internet]. Colombia: Cuenta de alto costo; 2008 [Actualizado el 30 junio 2015; citado 1 marzo 2016]. Disponible en: https://cuentadealtocosto.org/site/index.php/publicacionesMinisterio de Salud y Protección Social. [Internet]. Colombia: Ministerio de salud y protección social. Dirección de Epidemiología y Demografía. Grupo de Gestión de Conocimiento. 2014 [Actualizado el 1 de enero de 2014; citado 1 marzo de 2016] Disponible en https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/ED/G CFI/OERCAV_001%2022.10.2013%20v1.pdfBenjumea A., Manjarrés G, Arnoby J. Seguimiento de un programa de prediálisis en una unidad renal de la ciudad de Manizales. Rev. Colomb. Nefrol. 2015; 2(2):111–118.Escobar M; Registro Español de Enfermos Renales (REER). Registro Español de Enfermos Renales. Informe 2013 y evolución 2007-2013. Nefrología 2016;36(2):97–120López-Gómez JM, Abad S, Vega A. Nuevas expectativas en el tratamiento de la anemia en la enfermedad renal crónica. Nefrología. 2016; 36(3):232- 236.Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM.. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension. 2001;38(4):938-42.Perales Montilla CM, Duschek S, Reyes Del Paso GA. Calidad de vida relacionada con la salud en la enfermedad renal crónica: relevancia predictiva del estado de ánimo y la sintomatología somática. Nefrología. 2016 ;36(3):275-282Cheng S. Trastornos minerales y óseos. En: Daugirdas J. Manual de tratamiento de la enfermedad renal crónica. 1ra Edición. España: Wolters Kluwer; 2012. Página 107-126.Arango J, García A, Gómez R, Leguizamón H, Rodríguez K, Delgado V, et al. Recomendaciones para el manejo de las alteraciones del metabolismo óseo y mineral en el paciente con enfermedad renal crónica (EOMERC).Revista Colombiana de Nefrologia.2009Torregrosa JV, Bover J, Cannata Andía J, Lorenzo V, de Francisco AL, Martínez I, et al. Recomendaciones de la Sociedad Española de Nefrología para el manejo de las alteraciones del metabolismo óseo-mineral en los pacientes con enfermedad renal crónica (S.E.N.-M.M.). Nefrologia. 2011;31(Suppl.1):3-32Prieto S. Control del metabolismo del calcio, fósforo y magnesio. En: Tresguerres F, Ariznavarreta C, Cachofeiro V, Cardinali D, Loyzaga P, Lahera Juliá V, et al, editores. Fisiología Humana. 3ra Edición. México: McGraw-Hill; 2005. Pag 964-980Hall JE, Guyton AC. Tratado de fisiología medica. 12va Edición. España: Elsevier; 2011.Koeppen B, Stanton B. Berne y Levy: Fisiología. 6ta Edición. España: Elsevier; 2009.Potts JT; Jüppner H. Trastornos de las glándulas paratiroides y homeostasis del calcio. En: Longo D, Kasper D, Jameson J, et al, editores. Harrison: Principios de Medicina Interna. Volumen 18 Edición. México: Mc Graw Hill; 2012. Pág 3096- 3119.Fisiopatología del hueso y de la osteoporosis Dra. Amanda Páez Talero Médica Endocrinóloga, Universidad Nacional de Colombia Hospital Central de la Policía, Bogotá. Pag 12Salech F, Couve A, Michea L, Alvo M. Klotho: un nuevo eslabón en la fisiopatología de la insuficiencia renal crónica. Rev Hosp Clín Univ Chile. 2010;21:142-146Bover J. Egido J. Vitamina D, receptor de la vitamina D e importancia de su activación en el paciente con enfermedad renal crónica. Nefrologia 2015;35(1):28-41Bellorin-Font E, Ambrosoni P, Carlini R, et al. Guías de práctica clínica para la prevención, diagnóstico, evaluación y tratamiento de los trastornos minerales y óseos en la enfermedad renal crónica (TMO-ERC) en adultos. Nefrología 2013;33(Suppl.1):1-28Trujillo-Cuellar Hernando, Sierra-Lara Martínez J Daniel y Osorno-Solís Lucía. Alteraciones del metabolismo mineral y óseo asociadas a la enfermedad renal crónica. Revista Médica MD. 2015 5(3):151-160ppSellares VL, Torregrosa V. Alteraciones del metabolismo mineral en la enfermedad renal crónica estadios III, IV y V (no en diálisis). Nefrología (2008) Supl. 3, 67-78.United States Renal Data System, 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States. National Institutes of Health. National Institute of Diabetes Mellitus and Digestive and Kidney Diseases. Bethesda. 2014White SL, Chadban SJ, Jan S, Chapman JR, Cass A. How can we achieve global equity in provision of renal replacement therapy?. Bull World Health Organ. 2008; 86(3):229-237.Kovesdy CP1 , Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K. Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int. 2008;73(11):1296- 1302Collins AJ, Foley RN, Gilbertson DT, Chen SC. United States Renal Data System public health surveillance of chronic kidney disease and end-stage renal disease. Kidney Int Suppl (2011). 2015;5(1):2-7.Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010; 375(9731):2073-2081Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney int, Suppl. 2013; 3:1–150Uhlig K, Berns JS, Kestenbaum B, Kumar R, Leonard MB, Martin KJ, et al. KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis. 2010 May;55(5):773-99Nasrallah MM, El-Shehaby AR, Osman NA, Fayad T, Nassef A, Salem MM, et al. The association between fibroblast growth factor-23 and vascular 101 calcification is mitigated by inflammation markers. Nephron Extra. 2013;3(1):106-112.Dai B, David V, Martin A, Huang J, Li H, Jiao Y, et al. A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model. PLoS One. 2012;7(9):1–15, e44161Bover J, Egido J, Fernández-Giráldez E, Praga M, Solozábal-Campos C, Torregrosa JV, et al. Vitamina D, receptor de la vitamina D e importancia de su activación en el paciente con enfermedad renal crónica. Nefrologia 2015;35(1):28-41Silver J, Levi R. Regulation of PTH synthesis and secretion relevant to the management of secondary hyperparathyroidism in chronic kidney disease, Kidney Int Suppl. 2005;(95):Pag 8-12.Smith DH, Johnson ES, Thorp ML, Yang X, Neil N. Hyperparathyroidism in chronic kidney disease: a retrospective cohort study of costs and outcomes. J Bone Miner Metab. 2009;27(3):287-94Smith DH, Johnson ES, Thorp ML, Yang X, Neil N. Hyperparathyroidism in chronic kidney disease: a retrospective cohort study of costs and outcomes. J Bone Miner Metab. 2009;27(3):287-94Hogan J, Goldfarb S, Sterns R, Lam AQ. Regulation of calcium and phosphate balance. [Internet]. Up to Date. [11 dic 2014; citado 1 junio 2016]. Disponible en: http://www.uptodate.com.ezproxy.unilibrebaq.edu.co:8084/contents/regulati on-of-calcium-and-phosphatebalance?source=search_result&search=Regulation+of+calcium+and+phosp hate+balance&selectedTitle=1~150Hoenderop JG, Nilius B, Bindels RJ. Calcium absorption across epithelia. Physiol Rev. 2005;85(1):373-422Hoenderop JG, Nilius B, Bindels RJ. Calcium absorption across epithelia. Physiol Rev. 2005;85(1):373-422Hofer AM, Brown EM. Extracellular calcium sensing and signalling. Nat Rev Mol Cell Biol. 2003;4(7):530-538.Peng JB, Brown EM, Hediger MA. Apical entry channels in calciumtransporting epithelia. News Physiol Sci. 2003;18:158-63.Quarles LD. Endocrine functions of bone in mineral metabolism regulation. J Clin Invest. 2008;118(12):3820-3828.Quarles LD. Endocrine functions of bone in mineral metabolism regulation. J Clin Invest. 2008;118(12):3820-3828.Berndt T, Kumar R. Novel mechanisms in the regulation of phosphorus homeostasis. Physiology (Bethesda). 2009;24:17-25..Silver J, Naveh-Many T. Phosphate and the parathyroid. Kidney Int. 2009;75(9):898-905..Silver J, Naveh-Many T. Phosphate and the parathyroid. Kidney Int. 2009;75(9):898-905.Fuleihan GE, Brown E. Parathyroid hormone secretion and action. [Internet]. Up to date; [14 marzo 2014; 1 junio 2016]. Disponible en: http://www.uptodate.com.ezproxy.unilibrebaq.edu.co:8084/contents/parathyr oid-hormone-secretion-and- action?source=search_result&search=Parathyroid+hormone+secretion+and +action&selectedTitle=1~150.Chen Ra, Goodman WG. Role of the calcium-sensing receptor in parathyroid gland physiology. Am J Physiol Renal Physiol. 2004; 286(6):1005-1011.Karsenty G, Ferron M. The contribution of bone to whole-organism physiology. Nature. 2012;481(7381):314-320Toro L. Rol de Klotho y FGF23 en la regulación del fosfato y calcio plasmático, Rev Hosp Clin Univ Chile 2010;21:Pag 25–32Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997;390:45-51.Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, et al. Targeted ablation of FGF23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest. 2004;113(4):561–8.Ming CH, Shiizaki K, Kuro-o M, Moe OS. Fibroblast Growth Factor 23 and Klotho: Physiology and Pathophysiology of an Endocrine Network of Mineral Metabolism. Annu Rev Physiol. 2013; 75: 503–533.Chen CY, Kuro M, Razzaque MS. Molecular regulation of phosphate metabolism by fibroblast growth factor -23-khloto system. Advances in Chronic Kidney Disease. 2011; Vol 18, No 2: pp 91-97Haussler MR, Whitfield GK, Kaneko I, Forster R, Saini R, Hsieh JC, et al. The role of vitamin D in the FGF23, Klotho, and phosphate bone-kidney endocrine axis. Rev Endocr Metab Disord. 2012;13(1):57–69Yajima A, Tsuchiya K, Yokota H, Niita K. Bone disease in the field of CKDMBD. Clin Calcium. 2016;26(6):875-880Telci D, Dogan AU, Ozbek E, Polat EC, Simsek A, Cakir SS, et al. KLOTHO Gene Polymorphism of G395A Is Associated with Kidney Stones. Am J Nephrol. 2011; 33:337–343Akimoto T, Yoshizawa H, Watanabe Y, Numata A, Yamazaki T, Takeshima E, et al. Characteristics of urinary and serum soluble Klotho protein in patients with different degrees of chronic kidney disease. BMC Nephrology. 2012;13:155Shimamura Y, Hamada K, Inoue K, Ogata K, Ishihara M, et al. Serum levels of soluble secreted a-Klotho are decreased in the early stages of chronic kidney disease, making it a probable novel biomarker for early diagnosis, Clin Exp Nephrol.2012;16:722–729Young GH, Wu VC. KLOTHO methylation is linked to uremic toxins and chronic kidney disease, Kidney Int. 2012;81(7):611-612Specker BL, Tsang RC, Hollis BW. Effect of race and diet on human-milk vitamin D and 25-hydroxyvitamin D. Am J Dis Child.1985;139(11):1134- 1137.Wallace TC, Reider C, Fulgoni VL 3rd. Calcium and vitamin D disparities are related to gender, age, race, household income level, and weight classification but not vegetarian status in the United States: analysis of the NHANES 2001-2008 data set. J Am Coll Nutr. 2013; 32:321–330.Lamberg-Allardt C, Karkkainen M, Seppanen R, Bistrom H. Low serum 25- hydroxyvitamin D concentrations and secondary hyperparathyroidism in middle-aged white strict vegetarians. Am J Clin Nutr. 1993;58:684–689Barrett E, Barrett P. The parathyroid glands and vitamin D. En: Boron WF, Boulpaep EL, editors. Medical Physiology. 2nd Edition. United States of America: Elsevier; 2012.Pag 1094-1110Du X, Greenfield H, Fraser DR, Ge K, Trube A, Wang Y. Vitamin D deficiency and associated factors in adolescent girls in Beijing. Am J Clin Nutr. 2001;74(4):494–500Munns C, Zacharin MR, Rodda CP, et al. Prevention and treatment of infant and childhood vitamin D deficiency in Australia and New Zealand: A consensus statement. Med J Aust. 2006;185:268–272Van Cromphaut SJ, Dewerchin M, Hoenderop JG, et al. Duodenal calcium absorption in vitamin D receptor-knockout mice: Functional and molecular aspects. Proc Natl Acad Sci U S A. 2001;98(23):13324-13329Wasserman RH. Vitamin D and the intestinal absorption of calcium: A view and overview. In: Feldman D, Pike JW, Glorieux FH, eds. Vitamin D. San Diego (CA): Academic Press. 2005:411–428.Yamamoto Y, Yoshizawa T, Fukuda T, et al. Vitamin D receptor in osteoblasts is a negative regulator of bone mass control. Endocrinology. 2013;154(3):1008-1020.Slatopolsky E. The intact nephron hypothesis: the concept and its implications for phosphate management in CKD-related mineral and bone disorder. Kidney Int Suppl. 2011;(121):S3-8.Kovesdy CP, Kalantar-Zadeh K: Bone and mineral disorders in pre-dialysis CKD. Int Urol Nephrol.2008;40:427-440.Astudillo J, Cocio R, Ríos D. Osteodistrofia renal y trastornos del metabolismo y la mineralización ósea asociados a enfermedad renal crónica: Manifestaciones en radiología. Rev. chil. radiol. [Internet]. 2016 [citado 2016 Jun 10] ; 22( 1 ): 27-34. Disponible en: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717- 93082016000100008&lng=es. http://dx.doi.org/10.1016/j.rchira.2016.02.002Kumar R, Thompson JR. The regulation of parathyroid hormone secretion and synthesis. J Am Soc Nephrol. 2011;22(2):216-224.Melamed ML, Eustace JA, Plantiga LC, Jaar BG, et al. Third generation parathyroid hormone assay and all-cause mortality in incident patients: The CHOICE study. Nephrol Dial Transplant. 2008;23(5):1650-1658.Cole D, Webb S, Chan P. Update on parathyroid hormone: New tests and new challenges for external quality assessment. Clinical Biochemistry 2007; 40: 585–590Lillo J, Olea M. Hormona paratiroidea. Formas moleculares y utilidad diagnóstica. Ed cont lab clín; 13: 33-48Levin A, Hemmelgarn B, Culleton B, Tobe S, McFarlane P, Ruzicka M, et al. Canadian Society of Nephrology. Guidelines for the management of chronic kidney disease. CMAJ. 2008 Nov 18;179(11):1154-62.Kidney Disease Outcomes Quality Initiative KDOQI. Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Disponible en http://www.kidney.org/professionals/kdoqi/guidelines_bone/index.htmMartínez I, Saracho R, Ocharan J, Muñoz RJ, Montenegro J. Role of diet in the management of osteodystrophy during progressive renal insufficiency. Nefrologia 2003;23(Suppl 2):57-63.Giovannucci E. Can vitamin D reduce total mortality? Arch Intern Med 2007;167(16):1709-10Martínez I, Saracho R, Montenegro J, Llach F. The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis 1997;29(4):496-502Torregrosa JV, Ramos AM. Use of bisphosphonates in chronic kidney disease. Nefrologia 2010;30(3):288-96.Miller PD. Is there a role for bisphosphonates in chronic kidney disease? Semin Dial. 2007 May-Jun;20(3):186-90.Palmer SC, McGregor DO, Macaskill P, Craig JC, Elder GJ, Strippoli GF. Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med. 2007 Dec 18;147(12):840-53.Teng M, Wolf M, Lowrie E, Ofsthun N Lazaro JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003;349:446-56Taal MW. Slowing the progression of adult chronic kidney disease: therapeutic advances. Drugs. 2004;64(20):2273-89.Crawford PW, Lerma EV. Treatment options for end stage renal disease. Prim Care. 2008 Sep;35(3):407-32, v. Review.Murtagh FE, Addington-Hall JM, Donohoe P, Higginson IJ. Symptom management in patients with established renal failure managed without dialysis. EDTNA ERCA J. 2006 Apr-Jun;32(2):93-8.Sociedad Española de Diálisis y Trasplante (SEDYT). [sede Web]. Sánchez-Casajús A, Gabás J, Álvarez-Lipe R, Barceló P, Genovés A, Izaguirre A, et al. [Acceso Junio 8 de 2016]. Inicio de Diálisis: Consensos SEDYT ¿Cómo Y Cuándo Iniciar Diálisis? Disponible en: http://www.sedyt.org/2004/consensos/inicio_dialisis.htmZehnder C, Gutzwiller JP, Renggli K. Hemodiafiltration-a new treatment option for hyperphosphatemia in hemodialysis patients. Clin Nephrol 1999;52:152-9.Locatelli F, Buoncristiani U, Canaud B, Kohler H, Petitclerc T, Zucchelli P. Dialysis dose and frequency. Nephrol Dial Transplant 2005;20:285-96.Sprague SM, Abboud H, Qiu P, Dauphin M, Zhang P, Finn W. Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clin J Am Soc Nephrol. 2009 Jan;4(1):178-85Goldsmith DR, Scott LJ, Cvetkovic RS, Plosker GL. Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis. Drugs. 2008;68(1):85-104.Goldsmith DR, Scott LJ, Cvetkovic RS, Plosker GL. Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis. Drugs. 2008;68(1):85-104.Suki WN, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L et al. Effects of sevelamer and calcium-basel phosphate binders on mortality in hemodialysis patients. Kidney Int 2007;72:1130-7.Suki WN, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L et al. Effects of sevelamer and calcium-basel phosphate binders on mortality in hemodialysis patients. Kidney Int 2007;72:1130-7.Tentori F, Hunt WC, Stidley CA, Rohrscheib MR, Bedrick EJ, Meyer KB, Johnson HK, Zager PG; Medical Directors of Dialysis Clinic Inc. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int. 2006 Nov;70(10):1858-65.Cunningham J. New Vitamin D analogues for osteodystrophy in chronic kidney disease. Pediatr Nephrol. 2004 Jul;19(7):705-8.Cardus A, Panizo S, Parisi E, Fernández E, Valdivieso JM. Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res 2007;22:860-6. 62. Charra B, Chazot C, Jean G et al. Long 3 x 8 hr dialysis: a threedecade summary. J Nephrol 2003;(S7):S64-S69.Cardus A, Panizo S, Parisi E, Fernández E, Valdivieso JM. Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res 2007;22:860-6. 62. Charra B, Chazot C, Jean G et al. Long 3 x 8 hr dialysis: a threedecade summary. J Nephrol 2003;(S7):S64-S69.Arenas MD, Alvarez-Ude F, Gil MT, Moledous A, Malek T, Nuñez C et al. Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis. Nephrol Dial Transplant. 2007 Jun;22(6):1639-44.Garside R, Pitt M, Anderson R, Mealing S, Roome C, Snaith A et al. The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation. Health Technol Assess. 2007 May;11(18):iii, xi-xiii, 1-167.Palmer SC, Strippoli GF, McGregor DO. Interventions for preventing bone disease in kidney transplant recipients: a systematic review of randomized controlled trials. Am J Kidney Dis. 2005 Apr;45(4):638-49.Egbuna OI, Taylor JG, Bushinsky DA. Elevated calcium phosphate product after renal transplantation is a risk factor for graft failure. Clin Transplant 2007;21:558.Peters BS, Moyses RM, Jorgetti V, Martini LA. Effects of parathyroidectomy on bone remodeling markers and vitamin D status in patients with chronic kidney disease-mineral and bone disorder. Int Urol Nephrol. 2007;39(4):1251-6.Cejka D, Benesch T, Krestan C, Roschger P, Klaushofer K, Pietschmann P, et al. Effect of teriparatide on early bone loss after kidney transplantation. Am J Transplant 2008;8(9):1864-70.Wilmer WA, Magro CM. Calciphylaxis: emerging concepts in prevention, diagnosis, and treatment. Semin Dial 2004;15(3):172-86.Hayden MR, Goldsmith DJ. Sodium thiosulfate: new hope for the treatment of calciphylaxis. Semin Dial 2010;23(3):258-62.ORIGINALMONOGRAFIA HIPERPARATIROIDISMO SECUNDARIO EN ENFERMEDAD RENAL CRÓNICA.pdfMONOGRAFIA HIPERPARATIROIDISMO SECUNDARIO EN ENFERMEDAD RENAL CRÓNICA.pdfTrabajo de Gradoapplication/pdf2853375http://repository.unilibre.edu.co/bitstream/10901/10234/1/MONOGRAFIA%20HIPERPARATIROIDISMO%20SECUNDARIO%20EN%20ENFERMEDAD%20RENAL%20CR%c3%93NICA.pdf5ad84697961a7768bf5e32629d786423MD51LICENSElicense.txtlicense.txttext/plain; charset=utf-81748http://repository.unilibre.edu.co/bitstream/10901/10234/2/license.txt8a4605be74aa9ea9d79846c1fba20a33MD52THUMBNAILMONOGRAFIA HIPERPARATIROIDISMO SECUNDARIO EN ENFERMEDAD RENAL CRÓNICA.pdf.jpgMONOGRAFIA HIPERPARATIROIDISMO SECUNDARIO EN ENFERMEDAD RENAL CRÓNICA.pdf.jpgIM Thumbnailimage/jpeg4926http://repository.unilibre.edu.co/bitstream/10901/10234/3/MONOGRAFIA%20HIPERPARATIROIDISMO%20SECUNDARIO%20EN%20ENFERMEDAD%20RENAL%20CR%c3%93NICA.pdf.jpg01ab6ba395b7a3206f5556e6552a5672MD5310901/10234oai:repository.unilibre.edu.co:10901/102342022-10-11 12:08:26.616Repositorio Institucional Unilibrerepositorio@unilibrebog.edu.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

Publicaciones similares